SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tseng SCG, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody study. Cell. 1982; 30: 361372.
  • 2
    Makin CA, Borrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984; 37: 975983.
  • 3
    Schlimok G, Funke I, Holzmann B, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 1987; 84: 86728676.
  • 4
    Melchior SW, Corey E, Ellis WJ, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of prostate. Clin Cancer Res. 1997; 3: 249256.
  • 5
    Soeth E, Vogel I, Röder C, et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res. 1997; 57: 31063110.
  • 6
    Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991; 9: 17491756.
  • 7
    Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet. 1992; 340: 685689.
  • 8
    O'Sullivan GC, Collins JK, Kelly J, O'Brien F. Micrometastases in bone marrow of patients undergoing “curative” surgery for gastrointestinal cancer. Gastroenterology. 1995; 109: 15351540.
  • 9
    Thorban S, Roder JD, Nebarda H, Funk A, Siewert R, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 1996; 88: 12221227.
  • 10
    Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996; 347: 649653.
  • 11
    Poncelet AJ, Weynand B, Ferdin F, Robert AR, Noirhomme PH. Bone marrow micrometastasis might not be a short-term predictor of survival in early stage non-small cell lung carcinoma. Eur J Cardiothorac Surg. 2001; 20: 481488.
  • 12
    Hsu CP, Chen CY, Kwang PC, Miao J, Hsia JY, Shai SE: Bone marrow microinvolvement in non-small cell lung cancer is not a reliable indicator of tumor recurrence and prognosis. Eur J Surg Oncol. 2000; 26: 691695.
  • 13
    GreeneFL, PageDL, FlemingID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002: 191203.
  • 14
    Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32: 219229.
  • 15
    Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994; 3: 165173.
  • 16
    Mansi JL, Mesker WE, McDonnell T, Van Driel-Kulker AMJ, Ploem JS, Coombes RC. Automated screening for micrometastasis in bone marrow smears. J Immunol Methods. 1998; 112: 105111.
  • 17
    Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 1993; 53: 10271031.
  • 18
    Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung cancer. Ann Surg. 1995; 222: 415425.
  • 19
    Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg. 1997; 64: 363367.
  • 20
    Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol. 2001; 19: 36693674.
  • 21
    Matsunami K, Nakamura T, Oguma H, Kitamura Y, Takasaki K. Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation. Ann Surg Oncol. 2003; 10: 171175.
  • 22
    Putz E, Witter K, Offner S, et al. Phenotypic characteristics of cell lines derived from disseminated cancers in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 1999; 59: 241248.
  • 23
    Solakoglu O, Maierhofer C, Lahr G, et al. Heterogenous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA. 2002; 99: 22462251.
  • 24
    O'Sullivan GC, Collins JK, Kelly J, Morgan J, Madden M, Shanahan F. Micrometastases: marker of metastatic potential or evidence of residual disease? Gut. 1997; 40: 512515.
  • 25
    Janji B, Mechior C, Gouon V, Vallar L, Kieffer N. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlated with their metastatic phenotype. Int J Cancer. 1999; 83: 255262.
  • 26
    John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001; 7: 1423.
  • 27
    Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003; 97(3 Suppl ): 733738.